Vergelijking
FOXO4-DRI vs. Icatibant
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
2074706-72-8
138614-30-9
Molecuulmassa
3735 g/mol
1304.52 g/mol
Halfwaardetijd
0.5 h
geen gegevens
Sequentie
D-Retro-Inverso-Variante eines FOXO4-Peptid-Fragments (LTLRKEPASEIAQSILEAYSQNGWANRRSGGKR — D-Aminosäuren in umgekehrter Sequenz)geen gegevens
Werkingsmechanisme
FOXO4-DRI
FOXO4-DRI is the D-retro-inverso variant of a peptide fragment of the FOXO4 transcription factor. In senescent cells, FOXO4 is bound to p53, which suppresses p53-mediated apoptosis — the cells survive in a secreting 'zombie-like' state (senescence-associated secretory phenotype, SASP). The DRI peptide disrupts this FOXO4-p53 binding, freeing p53, and the senescent cell initiates apoptosis. Healthy cells are largely unaffected because p53 is not held back by FOXO4 in them. This selectivity was the central finding of the original 2017 publication.
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
Bewijsbasis
Hoogste bewijs
Diermodel
Humane RCT
Studies
3
1
waarvan bij mensen
0
1
Geregistreerde effecten
3
1
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between FOXO4-DRI and Icatibant?
- FOXO4-DRI is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". FOXO4-DRI: Synthetic peptide with D-Retro-Inverso structure (all amino acids as D-form, sequence reversed), developed in 2017 as an experimental senolytic candidate. Goal: selective apoptosis of senescent cells via disruption of the FOXO4-p53 interaction. So far evaluated exclusively preclinically. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, FOXO4-DRI or Icatibant?
- The highest available evidence level is "Diermodel" for FOXO4-DRI and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of FOXO4-DRI and Icatibant in Germany and the United States?
- Duitsland: FOXO4-DRI — Alleen onderzoek, Icatibant — Op recept. Verenigde Staten: FOXO4-DRI — Alleen onderzoek, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.